Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR...

Descripción completa

Detalles Bibliográficos
Autores principales: Skolariki, Aglaia, D’Costa, Jamie, Little, Martin, Lord, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400772/
https://www.ncbi.nlm.nih.gov/pubmed/36046843
http://dx.doi.org/10.37349/etat.2022.00078
_version_ 1784772815148285952
author Skolariki, Aglaia
D’Costa, Jamie
Little, Martin
Lord, Simon
author_facet Skolariki, Aglaia
D’Costa, Jamie
Little, Martin
Lord, Simon
author_sort Skolariki, Aglaia
collection PubMed
description The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR axis has emerged as an important driver of treatment failure, and inhibitors of mTOR and PI3K are now licensed for the treatment of women with advanced ER-positive breast cancer who have relapsed on first-line hormonal therapy. This review presents the preclinical and clinical data that led to this new treatment paradigm and discusses future directions.
format Online
Article
Text
id pubmed-9400772
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Open Exploration
record_format MEDLINE/PubMed
spelling pubmed-94007722022-08-30 Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic Skolariki, Aglaia D’Costa, Jamie Little, Martin Lord, Simon Explor Target Antitumor Ther Review The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR axis has emerged as an important driver of treatment failure, and inhibitors of mTOR and PI3K are now licensed for the treatment of women with advanced ER-positive breast cancer who have relapsed on first-line hormonal therapy. This review presents the preclinical and clinical data that led to this new treatment paradigm and discusses future directions. Open Exploration 2022 2022-04-24 /pmc/articles/PMC9400772/ /pubmed/36046843 http://dx.doi.org/10.37349/etat.2022.00078 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Skolariki, Aglaia
D’Costa, Jamie
Little, Martin
Lord, Simon
Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
title Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
title_full Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
title_fullStr Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
title_full_unstemmed Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
title_short Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
title_sort role of pi3k/akt/mtor pathway in mediating endocrine resistance: concept to clinic
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400772/
https://www.ncbi.nlm.nih.gov/pubmed/36046843
http://dx.doi.org/10.37349/etat.2022.00078
work_keys_str_mv AT skolarikiaglaia roleofpi3kaktmtorpathwayinmediatingendocrineresistanceconcepttoclinic
AT dcostajamie roleofpi3kaktmtorpathwayinmediatingendocrineresistanceconcepttoclinic
AT littlemartin roleofpi3kaktmtorpathwayinmediatingendocrineresistanceconcepttoclinic
AT lordsimon roleofpi3kaktmtorpathwayinmediatingendocrineresistanceconcepttoclinic

Ejemplares similares